ID

34005

Beschreibung

Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02192788

Link

https://clinicaltrials.gov/show/NCT02192788

Stichworte

Versionen (1)
  1. 10.01.19 10.01.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

10. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Oligometastatic Prostate Cancer NCT02192788

Englisch

Eligibility Oligometastatic Prostate Cancer NCT02192788

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with histologically confirmed prostate cancer, who are currently being oligometastases / oligorrecurrencia after primary treatment for their disease.
Beschreibung

Prostate carcinoma | Neoplasm Metastasis Few Post Primary treatment | Recurrence Few Post Primary treatment

Datentyp

boolean

Alias
UMLS CUI [1]
C0600139
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0205388
UMLS CUI [2,3]
C0687676
UMLS CUI [2,4]
C1708063
UMLS CUI [3,1]
C0034897
UMLS CUI [3,2]
C0205388
UMLS CUI [3,3]
C0687676
UMLS CUI [3,4]
C1708063
aged ≥ 18 years
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
time to biochemical recurrence more than 1 year
Beschreibung

Time Interval Recurrence Biochemical

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0872291
UMLS CUI [1,2]
C0034897
UMLS CUI [1,3]
C0205474
psa doubling time> 3 months
Beschreibung

Prostate-Specific Antigen Doubling Time

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0138741
UMLS CUI [1,2]
C2986483
less than 5 bone metastases location (including spinal) or lymph node.
Beschreibung

Secondary malignant neoplasm of bone Location Quantity | Secondary malignant neoplasm of spinal cord | Secondary malignant neoplasm of lymph node

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0153690
UMLS CUI [1,2]
C0450429
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0347016
UMLS CUI [3]
C0686619
without other metastases or recurrences by choline pet or / and nmr diffusion length.
Beschreibung

Neoplasm Metastasis Other Absent | Recurrence Other Absent | Choline PET | NMR

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0205394
UMLS CUI [1,3]
C0332197
UMLS CUI [2,1]
C0034897
UMLS CUI [2,2]
C0205394
UMLS CUI [2,3]
C0332197
UMLS CUI [3,1]
C0008405
UMLS CUI [3,2]
C0032743
UMLS CUI [4]
C0024485
signed and dated written informed consent form.
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients currently treatment with abiraterone, enzalutamide, chemotherapy, immunotherapy or radioisotopes.
Beschreibung

abiraterone | enzalutamide | Chemotherapy | Immunotherapy | Radioisotopes

Datentyp

boolean

Alias
UMLS CUI [1]
C0754011
UMLS CUI [2]
C3496793
UMLS CUI [3]
C0392920
UMLS CUI [4]
C0021083
UMLS CUI [5]
C0034595
patients unwilling or unable to comply with protocol requirements and scheduled visits.
Beschreibung

Protocol Compliance Unwilling | Protocol Compliance Unable

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0525058
UMLS CUI [1,2]
C0558080
UMLS CUI [2,1]
C0525058
UMLS CUI [2,2]
C1299582
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Oligometastatic Prostate Cancer NCT02192788

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Prostate carcinoma | Neoplasm Metastasis Few Post Primary treatment | Recurrence Few Post Primary treatment
Item
patients with histologically confirmed prostate cancer, who are currently being oligometastases / oligorrecurrencia after primary treatment for their disease.
boolean
C0600139 (UMLS CUI [1])
C0027627 (UMLS CUI [2,1])
C0205388 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1708063 (UMLS CUI [2,4])
C0034897 (UMLS CUI [3,1])
C0205388 (UMLS CUI [3,2])
C0687676 (UMLS CUI [3,3])
C1708063 (UMLS CUI [3,4])
Age
Item
aged ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Time Interval Recurrence Biochemical
Item
time to biochemical recurrence more than 1 year
boolean
C0872291 (UMLS CUI [1,1])
C0034897 (UMLS CUI [1,2])
C0205474 (UMLS CUI [1,3])
Prostate-Specific Antigen Doubling Time
Item
psa doubling time> 3 months
boolean
C0138741 (UMLS CUI [1,1])
C2986483 (UMLS CUI [1,2])
Secondary malignant neoplasm of bone Location Quantity | Secondary malignant neoplasm of spinal cord | Secondary malignant neoplasm of lymph node
Item
less than 5 bone metastases location (including spinal) or lymph node.
boolean
C0153690 (UMLS CUI [1,1])
C0450429 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0347016 (UMLS CUI [2])
C0686619 (UMLS CUI [3])
Neoplasm Metastasis Other Absent | Recurrence Other Absent | Choline PET | NMR
Item
without other metastases or recurrences by choline pet or / and nmr diffusion length.
boolean
C0027627 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0034897 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0008405 (UMLS CUI [3,1])
C0032743 (UMLS CUI [3,2])
C0024485 (UMLS CUI [4])
Informed Consent
Item
signed and dated written informed consent form.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
abiraterone | enzalutamide | Chemotherapy | Immunotherapy | Radioisotopes
Item
patients currently treatment with abiraterone, enzalutamide, chemotherapy, immunotherapy or radioisotopes.
boolean
C0754011 (UMLS CUI [1])
C3496793 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0021083 (UMLS CUI [4])
C0034595 (UMLS CUI [5])
Protocol Compliance Unwilling | Protocol Compliance Unable
Item
patients unwilling or unable to comply with protocol requirements and scheduled visits.
boolean
C0525058 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C1299582 (UMLS CUI [2,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video